Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Combined With Targeted Therapy and Immunotherapy in Advanced HCC
NCT07639138Phase 2Recruiting
- Sponsor
- SCG Cell Therapy
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in hepatocellular carcinoma (HCC), sponsored by SCG Cell Therapy. Primary endpoints: Incidence of Grade >=3 Treatment-Related Adverse Events and Progression-Free Survival Rate at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07639138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639138.